Net Income

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

RenX Enterprises touts massive growth after a reverse split, but a closer look reveals dilution risks, a heavy debt load, and a paid promotional campaign.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Benefits giant Alight is on the clock to save its NYSE listing after its stock price collapsed. Can a risky reverse stock split fix its deeper issues?

The company aims to slash production costs by 50% with AI, while deploying a powerful open-source agent that brings both promise and significant risk.

At its Hong Kong summit, Noah Holdings revealed a new playbook for global investors, leveraging AI to build resilient wealth structures in a changing world.

A landmark partnership brings AgriNext to North America, aiming to replace paperwork with a seamless digital experience for farmers and ranchers.

Neutech Group builds on its education, healthcare, and wellness strategy, but a closer look at its 2025 financials reveals a more complex picture.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

From a $20k loan to a major wellness player, a women-founded brand proves sustainability and science are the future of sleep and business.

The digital infrastructure firm secured new funding for expansion, but a steep discount in its offering has rattled investors and sent its share price plunging.

Firan Technology Group sets its Q1 earnings date. With a record 2025 behind it, all eyes are on whether it can sustain growth amid industry trends.

After a year of strategic shifts, Nortech Systems reports a strong Q4, signaling its restructuring efforts and nearshoring focus are finally paying off.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

INNOVATE Corp. reports a 62% Q4 revenue surge, but a 'going concern' warning and looming debt have forced the company to explore selling key assets.

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

EnerSys will unveil its strategic framework and technology roadmap, outlining its plan to navigate the energy transition and capitalize on market growth.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.